ISPOR Europe

Panel Discussion: Refining value assessment by considering indirect costs

Discover the benefits of broadening the scope of value assessment by incorporating evidence on the indirect burden of disease. We’ll explore its application in US value assessment and ex-US Health Technology Assessment (HTA) submissions.

Key discussion points

-Rare diseases often require a significant amount of medical care, which leads to a higher burden of direct medical costs.

-Indirect costs—such as productivity loss, absenteeism, lifestyle disruptions, and family and societal impacts—contribute to the overall burden of patients with rare disease and their caregivers.

-These broad indirect impacts are often overlooked and under-measured, leading to underestimation of the total disease burden in evidence used for value assessments and HTA submissions.

What you’ll learn

-Recent research measuring the indirect burden of disease

-How real-world evidence on indirect costs can be applied to value assessment and HTA submissions

-The potential impact of incorporating these insights on healthcare decision making